Rapalogs can promote cancer cell stemness in vitro in a Galectin-1 and H-ras-dependent manner

Currently several combination treatments of mTor- and Ras-pathway inhibitors are being tested in cancer therapy. While multiple feedback loops render these central signaling pathways robust, they complicate drug targeting. Here, we describe a novel H-ras specific feedback, which leads to an inadvert...

Descripción completa

Detalles Bibliográficos
Autores principales: Posada, Itziar M.D., Lectez, Benoit, Sharma, Mukund, Oetken-Lindholm, Christina, Yetukuri, Laxman, Zhou, Yong, Aittokallio, Tero, Abankwa, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546501/
https://www.ncbi.nlm.nih.gov/pubmed/28562352
http://dx.doi.org/10.18632/oncotarget.17819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546501/
https://www.ncbi.nlm.nih.gov/pubmed/28562352
http://dx.doi.org/10.18632/oncotarget.17819

Ejemplares similares